株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の多剤混合薬市場

The Global Market for Fixed-Dose Combination Drugs, 2012-2017

発行 STIX Market Research 商品コード 304371
出版日 ページ情報 英文 181 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。
Back to Top
世界の多剤混合薬市場 The Global Market for Fixed-Dose Combination Drugs, 2012-2017
出版日: 2013年12月31日 ページ情報: 英文 181 Pages
概要

多剤混合薬は、第二次、あるいは第三次治療法ではあるものの、高血圧などの特定の治療分野で時折使用されてきました。HIV感染患者に多剤混合薬を導入したことで生存率が上昇したことから、多剤混合薬の信頼性は上がり、他の疾患にも広く応用されるようになっています。過去数年で、数多くの多剤混合薬が様々な疾患に導入されています。

当レポートでは、様々な治療分野における多剤混合薬の導入動向、導入のメリットとデメリット、患者への適合性や有効性への影響、2012〜2017年の市場拡大予測などをまとめています。

イントロダクション

エグゼクティブサマリー

概要

  • 併用薬剤の定義
  • 多剤混合薬のメリット
    • 低用量と副作用の少なさ
    • 相乗効果としての治療効果
    • 早期治療標的
    • 相乗作用と解除
    • 適合性の向上
    • 管理コストの低減
    • 体の組織よりも病原体を標的とする
    • 製品群および治療の組み合わせ
    • 特許の延長
  • 多剤混合薬のデメリット
    • 用量比の管理ができない
    • 標準的には単剤療法
    • コスト管理
    • 法規制のインセンティブがない
    • 製造可能性の問題
    • 知的財産権の問題
    • 患者プール

製品および応用

  • 心血管疾患
    • 高血圧
    • 高コレステロール血症

糖尿病および内分泌異常

  • 糖尿病のための多剤混合薬
  • 糖尿病治療のための多剤混合薬市場

感染症

  • 主な多剤混合抗生剤
  • 最新感染治療のための多剤混合薬市場
  • ヘリコバクターピロリ感染
  • HIVおよびAIDS
  • 結核

自己免疫疾患

  • 多発性硬化症

精神疾患

  • 鬱病
  • 精神疾患治療のための多剤混合薬市場
  • 精神疾患治療のための第2相以降の多剤混合薬
  • アルツハイマー病治療のための多剤混合薬

呼吸器疾患

  • 喘息
  • COPD
  • 喘息治療のために現在上市されている製品
  • 喘息およびCOPDの治療薬市場
  • 喘息およびCOPD治療のための第2相以降の多剤混合薬
  • 癌およびその他の併用開発アプローチ
  • 多剤混合薬市場における主要メーカー

企業プロファイル

  • ABBOTT LABORATORIES
  • ASTRAZENECA PLC
  • APTALIS PHARMA
  • BRISTOL-MYERS SQUIBB
  • GILEAD SCIENCES INC
  • GLAXOSMITHKLINE PLC
  • HORIZON PHARMA USA
  • HORIZON PHARMA GMBH
  • MERCK & COMPANY, INC.
  • NOVARTIS AG
  • OREXIGEN THERAPEUTICS, INC
  • PFIZER INC.
  • SKYEPHARMA PLC.

図表

目次

Fixed-dose combination drugs have been used for some time in certain therapeutic categories such as antihypertensives, although they were often reserved for second- or third-line therapy. With the revolution in the survival rates of patients suffering from human immunodeficiency virus (HIV) infection that occurred with the implementation of fixed-drug combination products for this, this delivery technology received a boost of confidence as well as an influx of creative applications to other diseases. For the past several years, a number of fixed-dose combination drugs have been introduced for a variety of diseases, some for the first time in a particular disease category. With this in mind, this STIX Market Research report focuses on the impact of fixed-dose combination drug technology on various therapeutic categories, as well as providing assessments and projections of this technology overall and the impact on the patient compliance and effectiveness.. Specifically the aim of this report is to provide a range of information - from detailed market analyses through industry trends - to quantify and qualify the market for fixed-dose combination drugs for the treatment of selected major diseases. Forecasts and trends are gleaned from industry sources as well as from considered assessment of available and emerging technologies. The report develops forecasts for selected disease categories of the fixed-dose combination drug market from 2012 through 2017 and examines strategies employed by biotechnology companies and pharmaceutical firms to develop and market products in this market sector.

Table of Contents

  • INTRODUCTION
    • OBJECTIVES AND GOALS OF STUDY
    • INTENDED AUDIENCE
    • STUDY SCOPE AND FORMAT
    • METHODOLOGY
    • INFORMATION SOURCES
  • EXECUTIVE SUMMARY
  • OVERVIEW
    • DEFINITION OF A COMBINATION DRUG
    • ADVANTAGES OF FIXED-DOSE COMBINATION DRUGS
      • LOWER DOSES AND FEWER SIDE EFFECTS
      • SYNERGISTIC COMMON THERAPEUTIC EFFECT
      • EARLY TREATMENT TARGETS
      • POTENTIATION AND CANCELLATIONS
      • BETTER COMPLIANCE
      • LOWER ADMINISTRATIVE COSTS
      • TARGET INFECTIOUS AGENTS RATHER THAN BODY TISSUES
      • COMBINATION OF PRODUCT LINES AS WELL AS THERAPIES
      • PATENT EXTENSION
    • DISADVANTAGES OF FIXED-DOSE COMBINATION DRUGS
      • NO CONTROL OVER DOSAGE RATIOS
      • STANDARD PRACTICES EMPHASIZE MONOTHERAPY
      • COST CONTROL
      • REGULATORY DISINCENTIVES
      • MANUFACTURABILITY ISSUES
      • INTELLECTUAL PROPERTY ISSUES
      • PATIENT POOL
  • PRODUCTS AND APPLICATIONS
    • CARDIOVASCULAR DISEASES
      • HYPERTENSION
        • Prevalence of Hypertension Worldwide
        • Improved Control of Hypertension Needed
        • Combination Drugs Affecting More Control
        • Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure
        • Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure
        • Leading Single-Compound Antihypertensive Agents
        • Fixed-Dose Combination Antihypertensive Drugs
        • Drug Categories Commonly Used in Fixed-Dose Combination Antihypertensive Drugs
        • Angiotensin Converting Enzyme Inhibitors
          • Angiotensin II Receptor Blockers
          • Beta Blockers
          • Calcium Channel Blockers
          • Diuretics
        • Combination Therapy May Help Improve Rate of Survival with Favorable Neurological Status Following Cardiac Arrest
        • Market for Fixed-Dose Combination Antihypertensive Products
      • HYPERCHOLESTEROLEMIA
        • Relationship of Cholesterol to Cardiovascular Disease
        • Fixed-Dose Combination Lipid-Lowering Drugs
        • Marketed Statin Drugs
        • Fixed-Dose Combination Product to Treat Hypercholesterolemia
        • Potential Blockbuster Fails Late-Stage Trials
          • Simcor
          • "Polypill"
        • Single Combination Pill For Blood Pressure, Cholesterol, and Platelet Control Provides Benefit to Patients With or at Risk of CVD
  • DIABETES & ENDROCRINE
    • FIXED-DOSE COMBINATION DRUGS FOR DIABETES INTRODUCED
      • Avandamet
      • Glucovance
      • Metaglip
    • MARKET FOR FIXED-DOSE COMBINATION DRUGS TO TREAT DIABETES
  • INFECTIOUS DISEASES
    • LEADING FIXED-DOSE COMBINATION ANTIBIOTIC DRUGS
      • Augmentin
      • Bactrim
      • Primaxin
      • Synercid
      • Zosyn
      • Combination Drug Regimen Appears Beneficial for Patients with Hepatitis C and Unfavorable Treatment Characteristics
    • THE MARKET FOR FIXED-DOSE COMBINATION DRUGS TO TREAT BACTERIAL INFECTIONS
    • HELICOBACTER PYLORI INFECTION
      • Fixed-Dose Combination Therapy for the Treatment of Helicobacter Pylori Infections/Duodenal Ulcers
        • OD-PEP
        • Pylera
      • Market for Fixed-Dose Combination Drugs to Treat H. Pylori Infections
    • HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS)
      • HIV and AIDS Statistics
      • HIV Infection and AIDS Cases in the U.S.
      • Treatments for HIV Infection/AIDS
      • Categories of Drugs Used in Fixed-Dose Combination Products for the Treatment of HIV/AIDS
        • Entry and Fusion Inhibitors
        • Reverse Transcriptase Inhibitors
          • Nonnucleoside Reverse Transcriptase Inhibitors
          • Nucleoside Reverse Transcriptase Inhibitors
          • Nucleotide Reverse Transcriptase Inhibitors
          • Protease Inhibitors
          • Integrase Inhibitors
        • AbbVie's Investigational HCV Regimen Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration
      • Side Effects of Marketed HIV Drugs
      • HIV/AIDS Drugs Introduced to the U.S. Market from 2006 through 2013
      • Leading Marketers of HIV/AIDS Drugs
      • Dosing and Compliance Challenges
      • The Ideal Dosing Regimen and the Role of Fixed-Dose Combination Products
      • The Number of Salvage Patients Continues to Increase
      • Fixed-Dose Combination Drugs to Treat HIV/AIDS
        • Combination Products Emerge as Preferred Treatment
        • Atripla
        • Combivir
        • Complera
        • Epzicom
        • Kaletra
        • Prezista
        • Stribild
        • Trizivir
        • Truvada
      • The Market for Fixed-Dose Combination Drugs for the Treatment of HIV Infection/AIDS
      • Most Recent FDA Developments
    • TUBERCULOSIS
      • Tuberculosis in Children
      • Fixed-Dose Combination Drugs Used to Treat Tuberculosis
  • AUTOIMMUNE DISEASES
    • MULTIPLE SCLEROSIS
    • Fixed-Dose Combination Drugs Used to Treat Multiple Sclerosis
  • PSYCHIATRIC DISORDERS
    • DEPRESSION
      • Fixed-Dose Combination Products for the Treatment of Depression
      • Scripps Research Institute Approach to Cocaine Abuse
    • MARKET FOR FIXED-DOSE COMBINATION PRODUCTS TO TREAT PSYCHIATRIC DISORDERS
    • FIXED-DOSE COMBINATION PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF PSYCHIATRIC DISORDERS
      • 372475
      • 773812
      • Contrave
      • Empatic (formerly Excalia)
      • Symbyax
    • FIXED-DOSE COMBINATION PRODUCTS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
  • RESPIRATORY DISEASES
    • ASTHMA
    • CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
    • CURRENT MARKETED PRODUCTS FOR THE TREATMENT OF ASTHMA
      • Anti-Inflammatory Drugs Used to Treat Asthma
        • Corticosteroids
        • Leukotriene Modifiers
        • IgE Inhibitors
        • Phosphodiesterase Inhibitors
        • Mast-Cell Inhibitors
      • Efficacy of Available Drugs
      • Fixed-Dose Combination Asthma Treatments
        • Advair/Seretide
        • Foster
        • Symbicort
    • THE MARKET FOR DRUGS TO TREAT ASTHMA AND COPD
      • The Market for Drugs to Treat Asthma
      • The Market Drugs to Treat COPD
    • FIXED-DOSE COMBINATION PRODUCTS IN PHASE II OR LATER DEVELOPMENT TO TREAT ASTHMA AND COPD
      • Alvesco Combo
      • Flutiform
      • Breo Ellipta (Relovair or Super Advair)
      • VR315
    • CANCER AND OTHER COMBINATIONAL DEVELOPMENTAL APPROACHES RECENT DEVELOPMENTS
      • The Institute of Cancer Research
      • Arthur G. James Cancer Hospital
      • Celgene Corporation
      • Medical Therapy of Prostatic Symptoms (MTOPS) Trial
      • Virginia Commonwealth University
      • University of Texas MD Anderson Cancer Center
    • LEADING MANUFACTURERS IN THE FIXED-DOSE COMBINATION DRUG MARKET
  • COMPANY PROFILES
    • ABBOTT LABORATORIES
    • ASTRAZENECA PLC
    • APTALIS PHARMA
    • BRISTOL-MYERS SQUIBB
    • GILEAD SCIENCES INC
    • GLAXOSMITHKLINE PLC
    • HORIZON PHARMA USA
    • HORIZON PHARMA GMBH
    • MERCK & COMPANY, INC.
    • NOVARTIS AG
    • OREXIGEN THERAPEUTICS, INC
    • PFIZER INC.
    • SKYEPHARMA PLC.
Back to Top